The University of Pittsburgh Cancer Institute (UPCI) Investigational Drug Service (IDS) is directed by Brian M. Miller, PharmD who is assisted by Elizabeth A. Paul, RPh and a pharmacy technician, Kristine M. Fischl. In addition, the clinic pharmacy that works in tandem with the IDS has three full-time pharmacy technicians, four full-time pharmacists, and two part-time pharmacists. These individuals also participate in treating patients enrolled in protocol treatments mainly through order-entry, mixing chemotherapy, and dispensing provided oral medication. The IDS oversees all pharmacy procedures and processes at the UPCI central and community clinical sites and the Clinical and Translational Research Center (CTRC) where UPCI sponsored studies are implemented and most Phase I studies take place. The IDS coordinate all pharmacy procedures associated with UPCI drug-related research protocols. The goal of the IDS is to ensure that the procurement, receipt, storage, accountability, preparation, dispensing, labeling, and shipping of investigational drugs are performed in accordance with all state and federal laws, Joint Commission on Accreditation of Healthcare Organizations (JCAHO), and the local IRB approved protocol guidelines. Clinical recommendations for drug therapy, monitoring plans for a regimen, managing adverse events, and dose calculations are made with respect to the treatment of patients. Additional responsibilities of the IDS include reviewing all approved IRB protocols, standard chemotherapy and protocol regimens, supportive care regimens (antiemetics and other premedications), and investigational drug policies and procedures. UPCI's Off-site locations require special efforts to ensure rigorous and successful implementation, coordination, and monitoring clinical protocols. Throughout the entire network of cancer sites, the IDS provides oversight and monitoring for all pharmacy related activities. IDS also implements a quality assurance program, which includes labeling drugs per protocol and placing specific labeling on each medication to ensure proper dispensing, and an education program of pharmacists and/or pharmacy technicians for new protocols and treatments, inventory control, and optimized patient care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-26
Application #
8705418
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$46,566
Indirect Cost
$15,761
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Chen, Lin; Vasilatos, Shauna N; Qin, Ye et al. (2017) Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression. Oncotarget 8:81737-81753
Kurland, Brenda F; Linden, Hannah M; Mankoff, David A (2017) FDG PET and FES PET Predict PFS on Endocrine Therapy-Response. Clin Cancer Res 23:3475
Jing, Y; Nguyen, M M; Wang, D et al. (2017) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene :
Lee-Montiel, Felipe T; George, Subin M; Gough, Albert H et al. (2017) Control of oxygen tension recapitulates zone-specific functions in human liver microphysiology systems. Exp Biol Med (Maywood) 242:1617-1632
Gao, Ying; Li, Changling; Wei, Leizhen et al. (2017) SSRP1 Cooperates with PARP and XRCC1 to Facilitate Single-Strand DNA Break Repair by Chromatin Priming. Cancer Res 77:2674-2685
Xie, Yangchun; Zhu, Shan; Zhong, Meizuo et al. (2017) Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma. Gastroenterology 153:1429-1443.e5
von Gruenigen, Vivian E; Huang, Helen Q; Beumer, Jan H et al. (2017) Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecol Oncol 144:459-467
Pascal, Laura E; Masoodi, Khalid Z; Liu, June et al. (2017) Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia. J Endocrinol 235:123-136
Tarhini, Ahmad A; Rafique, Imran; Floros, Theofanis et al. (2017) Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 123:2936-2944
Lothet, Emilie H; Shaw, Kendrick M; Lu, Hui et al. (2017) Selective inhibition of small-diameter axons using infrared light. Sci Rep 7:3275

Showing the most recent 10 out of 1045 publications